Also mentions Nasdaq:
NASDAQ OMX Reports Record Fourth Quarter 2013 Results
x hide permanently

Surface Oncology Appoints Carsten Brunn to Board of Directors


Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company’s board of directors...

Mentions: Nasdaq Surface Oncology Target